When your body's defense system turns into a factory of dysfunction
In short: Multiple myeloma is a blood cancer that hijacks plasma cells—the very white blood cells responsible for making antibodies. Instead of protecting you from germs, these cancerous cells flood the bone marrow with abnormal proteins, eventually damaging vital organs like your kidneys.
The pathology begins in the bone marrow, where healthy plasma cells are normally tasked with producing antibodies to fight infection. In multiple myeloma, these cells undergo aberrant growth and begin churning out monoclonal proteins (or M proteins). Unlike functional antibodies, these abnormal proteins can accumulate in the bloodstream and urine, leading to significant organ damage, particularly renal impairment.
Clinically, the disease is categorized by its severity and progression. 'Smoldering' multiple myeloma involves a plasma cell condition without immediate organ damage or bone lesions, often requiring observation rather than immediate intervention. In contrast, 'active' multiple myeloma is diagnosed when testing reveals at least one myeloma-defining event, such as severe renal impairment, anemia, hypercalcemia, or significant bone loss.
The disease also shares a lineage with other blood cancers but remains distinct in its origin: while leukemia involves non-usual white blood cells and lymphoma starts in lymphocytes, multiple myeloma is specifically rooted in plasma cells. It often follows a precursor condition called monoclonal gammopathy of undetermined significance (MGUS), where protein levels are low enough that they do not yet cause organ damage.
Current treatment strategies aim to control the disease, reduce complications, and extend life through medicines and stem cell transplants. Because myeloma cells are highly secretory, researchers are investigating new pathways like RNA polymerase I inhibition to target their dependence on translation pathways. Despite these advancements, it remains a complex illness characterized by potential relapses at various stages of progression.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Multiple Myeloma - signs and symptoms, pathophysiology, treatment
- Also: Multiple myeloma - Symptoms and causes
- Also: Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics
- Also: my.clevelandclinic.org — What Is Multiple Myeloma?
To cite this card, link to https://intellectplus.co.uk/app/science-multiple-myeloma-signs-and-symptoms-pathophysiology-treatmen.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
